James George Chopas Sells 1,096 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CAO James George Chopas sold 1,096 shares of the business’s stock in a transaction on Wednesday, January 22nd. The stock was sold at an average price of $30.43, for a total transaction of $33,351.28. Following the completion of the sale, the chief accounting officer now owns 48,138 shares in the company, valued at $1,464,839.34. This represents a 2.23 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

James George Chopas also recently made the following trade(s):

• On Friday, January 17th, James George Chopas sold 715 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $29.96, for a total transaction of $21,421.40.
• On Monday, January 13th, James George Chopas sold 783 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $28.70, for a total transaction of $22,472.10.

Apellis Pharmaceuticals Price Performance

Shares of NASDAQ:APLS traded up $0.37 during midday trading on Thursday, reaching $30.76. 1,345,028 shares of the company’s stock traded hands, compared to its average volume of 2,139,207. Apellis Pharmaceuticals, Inc. has a 1 year low of $24.34 and a 1 year high of $71.90. The company has a market cap of $3.83 billion, a P/E ratio of -15.15 and a beta of 0.94. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36. The company has a fifty day simple moving average of $31.95 and a two-hundred day simple moving average of $33.25.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The business had revenue of $196.83 million for the quarter, compared to analysts’ expectations of $200.00 million. During the same quarter last year, the business earned ($1.17) EPS. The company’s quarterly revenue was up 78.3% on a year-over-year basis. Equities analysts predict that Apellis Pharmaceuticals, Inc. will post -1.71 EPS for the current fiscal year.

Analyst Ratings Changes

APLS has been the subject of a number of research reports. Robert W. Baird lowered their price objective on shares of Apellis Pharmaceuticals from $92.00 to $55.00 and set an “outperform” rating for the company in a research note on Thursday, November 7th. Wells Fargo & Company cut their price objective on shares of Apellis Pharmaceuticals from $43.00 to $30.00 and set an “equal weight” rating on the stock in a report on Wednesday, November 6th. HC Wainwright restated a “buy” rating and set a $57.00 price objective on shares of Apellis Pharmaceuticals in a report on Tuesday, January 14th. Bank of America cut their price objective on shares of Apellis Pharmaceuticals from $61.00 to $47.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Finally, Morgan Stanley began coverage on shares of Apellis Pharmaceuticals in a report on Thursday, November 21st. They set an “equal weight” rating and a $31.00 price objective on the stock. Eight investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $46.71.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. KBC Group NV lifted its holdings in Apellis Pharmaceuticals by 3,862.3% in the 4th quarter. KBC Group NV now owns 104,287 shares of the company’s stock valued at $3,328,000 after purchasing an additional 101,655 shares in the last quarter. Merit Financial Group LLC purchased a new position in Apellis Pharmaceuticals in the 4th quarter valued at $254,000. Hennion & Walsh Asset Management Inc. lifted its holdings in Apellis Pharmaceuticals by 135.6% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 29,740 shares of the company’s stock valued at $949,000 after purchasing an additional 17,115 shares in the last quarter. Eastern Bank lifted its holdings in Apellis Pharmaceuticals by 87.0% in the 4th quarter. Eastern Bank now owns 21,500 shares of the company’s stock valued at $686,000 after purchasing an additional 10,000 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in Apellis Pharmaceuticals by 23.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 3,884,730 shares of the company’s stock valued at $112,036,000 after purchasing an additional 735,160 shares in the last quarter. Hedge funds and other institutional investors own 96.29% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).